Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Accumulated Expenses (2024 - 2025)

Pelthos Therapeutics has reported Accumulated Expenses over the past 2 years, most recently at $15.4 million for Q4 2025.

  • Quarterly results put Accumulated Expenses at $15.4 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $15.4 million (changed N/A YoY), and the annual figure for FY2025 was $15.4 million, changed.
  • Accumulated Expenses for Q4 2025 was $15.4 million at Pelthos Therapeutics, up from $11.9 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for PTHS hit a ceiling of $15.4 million in Q4 2025 and a floor of $308.0 in Q3 2024.